- Home
- ADAP vs SRZN Comparison
ADAP vs SRZN Comparison
Compare ADAP & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- SRZN
- Stock Information
- Founded
- ADAP 2008
- SRZN 2015
- Country
- ADAP United Kingdom
- SRZN United States
- Employees
- ADAP N/A
- SRZN 41
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- ADAP Health Care
- SRZN Health Care
- Exchange
- ADAP Nasdaq
- SRZN Nasdaq
- Market Cap
- ADAP 75.5M
- SRZN 65.5M
- IPO Year
- ADAP 2015
- SRZN N/A
- Fundamental
- Price
- ADAP $0.28
- SRZN $8.49
- Analyst Decision
- ADAP Buy
- SRZN Strong Buy
- Analyst Count
- ADAP 6
- SRZN 2
- Target Price
- ADAP $1.52
- SRZN $38.50
- AVG Volume (30 Days)
- ADAP 1.6M
- SRZN 13.0K
- Earning Date
- ADAP 05-13-2025
- SRZN 05-09-2025
- Dividend Yield
- ADAP N/A
- SRZN N/A
- EPS Growth
- ADAP N/A
- SRZN N/A
- EPS
- ADAP N/A
- SRZN N/A
- Revenue
- ADAP $179,639,000.00
- SRZN $11,638,000.00
- Revenue This Year
- ADAP N/A
- SRZN N/A
- Revenue Next Year
- ADAP $52.49
- SRZN N/A
- P/E Ratio
- ADAP N/A
- SRZN N/A
- Revenue Growth
- ADAP 878.53
- SRZN N/A
- 52 Week Low
- ADAP $0.20
- SRZN $5.90
- 52 Week High
- ADAP $1.48
- SRZN $18.17
- Technical
- Relative Strength Index (RSI)
- ADAP 49.68
- SRZN 49.02
- Support Level
- ADAP $0.26
- SRZN $5.90
- Resistance Level
- ADAP $0.30
- SRZN $8.52
- Average True Range (ATR)
- ADAP 0.03
- SRZN 0.79
- MACD
- ADAP 0.00
- SRZN 0.15
- Stochastic Oscillator
- ADAP 54.53
- SRZN 82.75
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).